Cleveland Clinic | Strategic Alliance Partners

November 01, 2016

Samuel Chao, MD, Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, discusses spine stereotactic radiosurgery for the treatment of metastases located on the spine.

October 26, 2016

Vamsidhar Velcheti, MD, an assistant professor of Medicine at Cleveland Clinic Lerner School of Medicine, discusses the ALK inhibitor alectinib (Alecensa) and what potential the agent could have in the frontline setting for patients with ALK-positive non–small cell lung cancer (NSCLC). Velcheti shared this insight in an interview during the 2016 OncLive State of the Science Summit on Non–Small Cell Lung Cancer.

October 05, 2016

Kevin Stephans, MD, associate staff, Radiation Oncology at Cleveland Clinic, discusses advancements in the treatment of patients with oligometastatic lung cancer.

September 20, 2016

Despite the fervent advocacy of stereotactic radiosurgery alone, the addition of whole-brain radiation therapy clearly improves local control, decreases distant brain failure, minimizes the need for salvage therapies such as surgery, and, most importantly, decreases neurologic death.

September 08, 2016

James Stevenson, MD, medical oncologist at Cleveland Clinic, discusses the potential of immunotherapy agents as treatment for patients with squamous non–small cell lung cancer (NSCLC).

September 08, 2016

Jorge A. Garcia, MD, discusses the final survival data from the phase III METEOR trial, which was the basis for cabozantinib's (Cabometyx's) FDA approval, as well as the role the agent will now play along with nivolumab (Opdivo) in advanced RCC.

August 31, 2016

Nathan Pennell, MD, PhD, associate professor of Medicine at Cleveland Clinic, discusses the importance of testing patients with non–small cell lung cancer (NSCLC) to determine if they harbor the EGFR mutation, as well as the agents available to target that genetic abnormality.

April 24, 2016

Although precision oncology has promise, its success hinges on the availability of clinical trials of targeted therapies.

March 09, 2016

Jorge Garcia, MD, discusses CheckMate-025, the challenges with PD-1 as a biomarker, additional potential biomarkers, and why combination immunotherapy in renal cell carcinoma is still a work in progress.

December 26, 2015

One of the central reasons that curing cancer has been so problematic is the dysfunction of TP53, the single most common genetic alteration in cancer.

October 19, 2015

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discusses a phase Il study that examined axitinib as a second-line therapy for metastatic renal cell carcinoma.

October 15, 2015

The IMA901 multipeptide vaccine added to sunitinib failed to improve outcomes versus sunitinib alone as first-line therapy for advanced/metastatic renal cell carcinoma.

October 07, 2015

Aziz Nazha, MD, hematologist, Leukemia Program at the Cleveland Clinic, Taussig Cancer Institute, discusses results of a mutational model to predict response to hypomethylating agents in myelodysplastic syndromes (MDS).

September 18, 2015

Hetty Carraway, MD, Hematology and Oncology, Cleveland Clinic, discusses combination epigenetic therapies including aza-nucleosides and histone deacetylase inhibitors, as well as immunomodulatory therapies, such as lenalidomide for the treatment of myelodysplastic syndromes (MDS).

September 16, 2015

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

September 09, 2015

Davendra Sohal, MD, MPH, oncologist and Director of the Clinical Genomics Program at the Cleveland Clinic Taussig Cancer Institute, discusses the feasibility of standardizing genomic profiling and apply precision medicine techniques.

September 04, 2015

James Stevenson, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute (TCI), discusses the impact of a stage IV non-small-cell lung cancer (NSCLC) care pathway on front-line and maintenance chemotherapy.

September 02, 2015

Alberto Montero, MD Staff Physician in the Department of Solid Tumor Oncology, Cleveland Clinic, discusses reducing readmission rates for oncology patients.

September 01, 2015

OncLive today announced it is teaming up with Cleveland Clinic, ranked a top-five hospital by U.S. News & World Report, to provide breaking news and information about the hospital's pioneering research and care for cancer patients. Editorial and marketing groups within OncLive, which provides oncologists resources and information they need to deliver the best care for their patients, will focus on many cancer-related programs and initiatives at Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education.

June 23, 2015

Marc Ernstoff, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses results from a study examining the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced BRAF-mutated or BRAF wild-type melanoma.